Country for PR: China
Contributor: Xinhua News Agency
Monday, February 06 2023 - 18:27
BGI COLOTECT 3.0 demonstrates higher colorectal cancer detection sensitivity than FIT
SAN FRANCISCO, Feb. 6, 2023 /Xinhua-AsiaNet/--

COLOTECT 3.0, a multi-target fecal DNA test outperforms fecal immunochemical 
tests (FIT) in terms of detection of colorectal cancer and advanced 
precancerous lesions

BGI Genomics, a global life sciences company providing integrated solutions of 
precision medicine, presented case-control study data on its COLOTECT 3.0 
non-invasive colorectal cancer screening test at the 2023 ASCO Gastrointestinal 
Cancers Symposium (ASCO GI 2023) and announced plans for further global 
clinical studies. 

According to data released during ASCO GI 2023, in a recently concluded 
multi-center case-control study, BGI Genomics collected stool specimens from a 
total of 783 subjects with Colorectal cancer (CRC), advanced precancerous 
lesions (APL), non-advanced neoplasms and individuals with negative findings on 
colonoscopy from six sites across China. All participants underwent 
colonoscopy. Stool specimens from these participants were tested with the 
COLOTECT 3.0 multi-target fecal DNA test as well as a quantitative Fecal 
immunochemical test (FIT) (OC FIT-CHEK, Eiken) in parallel to perform 
head-to-head comparison of the test performance of both assays. 

COLOTECT 3.0, a multi-target fecal DNA test demonstrated higher sensitivity 
(96.1%) than FIT (85.8%) for CRCs (n=204). Meanwhile, 52.5% of patients (n=40) 
with APL tested positive by COLOTECT 3.0, which was remarkably superior to FIT 
(22.5%). Among 539 participants with non-advanced neoplasms or negative 
findings on colonoscopy, the specificity of COLOTECT 3.0 was 87.4%, compared 
with a specificity of 93.1% achieved by FIT. 

COLOTECT 3.0 is a novel multi-target fecal DNA based assay, which integrates 
detection of two stool DNA (sDNA) methylation markers by quantitative 
methylation specific PCR (qMSP) and immunochemical fecal occult blood test.

COLOTECT 3.0 has obtained CE certification and MHRA approval. For product 
details and availability, please contact

Fang Zhang

Source: BGI Genomics

Image Attachments Links:


   Caption: ASCO GI 2023 Sensitivity and specificity of the multi-target fecal 
DNA test of COLOTECT 3.0 poster